$ARTH
Arch Therapeutics, Inc.

2024 Q2 Form 10-Q Financial Statement

#000143774924015699 Filed on May 09, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue $30.91K $31.87K
YoY Change 132.55% 91.34%
Cost Of Revenue $21.08K $21.56K
YoY Change 13.76% 15.16%
Gross Profit $9.834K $10.31K
YoY Change -287.82% -599.56%
Gross Profit Margin 31.81% 32.36%
Selling, General & Admin $875.6K $683.2K
YoY Change 0.64% -45.47%
% of Gross Profit 8904.1% 6625.78%
Research & Development $155.7K $203.9K
YoY Change 11.96% 19.48%
% of Gross Profit 1583.09% 1977.2%
Depreciation & Amortization $380.00 $560.00
YoY Change 39.19% 47.37%
% of Gross Profit 3.86% 5.43%
Operating Expenses $1.031M $887.1K
YoY Change 2.2% -37.68%
Operating Profit -$1.021M -$876.7K
YoY Change 0.7% -38.5%
Interest Expense -$671.9K $592.4K
YoY Change -183.08% -6.74%
% of Operating Profit
Other Income/Expense, Net -$4.633M -$592.4K
YoY Change 472.87% -213.27%
Pretax Income -$5.655M -$1.469M
YoY Change 210.17% 62.79%
Income Tax
% Of Pretax Income
Net Earnings -$5.655M -$1.469M
YoY Change 210.17% 62.79%
Net Earnings / Revenue -18292.24% -4610.37%
Basic Earnings Per Share -$1.44 -$0.33
Diluted Earnings Per Share -$1.44 -$0.33
COMMON SHARES
Basic Shares Outstanding 4.444M 4.742M
Diluted Shares Outstanding 4.444M shares

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $30.03K $26.43K
YoY Change -65.3% -10.41%
Cash & Equivalents $30.03K $26.43K
Short-Term Investments
Other Short-Term Assets $40.82K $177.2K
YoY Change -54.91% 13.31%
Inventory $1.320M $1.330M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $1.391M $1.533M
YoY Change -10.83% -3.47%
LONG-TERM ASSETS
Property, Plant & Equipment $3.014K $3.390K
YoY Change 314.01% 238.66%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $3.500K $3.500K
YoY Change 0.0% 0.0%
Total Long-Term Assets $6.514K $6.890K
YoY Change 54.07% 53.08%
TOTAL ASSETS
Total Short-Term Assets $1.391M $1.533M
Total Long-Term Assets $6.514K $6.890K
Total Assets $1.398M $1.540M
YoY Change -10.65% -3.31%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.917M $2.970M
YoY Change 18.03% 22.41%
Accrued Expenses $1.653M $1.390M
YoY Change 61.93% 63.25%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $9.388M $6.898M
YoY Change 75.58% 55.51%
Total Short-Term Liabilities $13.96M $12.42M
YoY Change 45.71% 55.63%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $13.96M $12.42M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $13.96M $12.42M
YoY Change 45.71% 55.63%
SHAREHOLDERS EQUITY
Retained Earnings -$72.59M -$66.21M
YoY Change 21.8% 14.59%
Common Stock $60.03M $55.33M
YoY Change 16.38% 7.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$12.56M -$10.88M
YoY Change
Total Liabilities & Shareholders Equity $1.398M $1.540M
YoY Change -10.65% -3.31%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$5.655M -$1.469M
YoY Change 210.17% 62.79%
Depreciation, Depletion And Amortization $380.00 $560.00
YoY Change 39.19% 47.37%
Cash From Operating Activities -$911.7K -$700.1K
YoY Change 1.57% 16.72%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 915.2K 520.7K
YoY Change -4.12% -15.84%
NET CHANGE
Cash From Operating Activities -911.7K -700.1K
Cash From Investing Activities
Cash From Financing Activities 915.2K 520.7K
Net Change In Cash 3.600K -179.4K
YoY Change -93.69% -1049.81%
FREE CASH FLOW
Cash From Operating Activities -$911.7K -$700.1K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
332087 usd
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
1442138 usd
us-gaap Costs And Expenses
CostsAndExpenses
2449144 usd
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-876742 usd
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
ARCH THERAPEUTICS, INC.
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
4444363
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
362866 usd
CY2024Q1 us-gaap Assets Current
AssetsCurrent
1533177 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
1950090 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1958189 usd
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-6386088 usd
us-gaap Net Income Loss
NetIncomeLoss
-4150791 usd
us-gaap Net Income Loss
NetIncomeLoss
-2702533 usd
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Entity File Number
EntityFileNumber
000-54986
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
431-2313
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 us-gaap Cash
Cash
26426 usd
CY2023Q3 us-gaap Cash
Cash
222720 usd
CY2024Q1 us-gaap Inventory Net
InventoryNet
1329593 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
1364504 usd
CY2024Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
177158 usd
CY2023Q3 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
467496 usd
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
46-0524102
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
NV
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
235 Walnut Street, Suite 6
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--09-30
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001537561
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false
CY2023Q3 us-gaap Derivative Liability Number Of Instruments Held
DerivativeLiabilityNumberOfInstrumentsHeld
0 pure
CY2024Q1 us-gaap Derivative Liability Number Of Instruments Held
DerivativeLiabilityNumberOfInstrumentsHeld
0 pure
CY2023Q1 us-gaap Inventory Write Down
InventoryWriteDown
0 usd
CY2024Q1 us-gaap Inventory Write Down
InventoryWriteDown
0 usd
CY2024Q1 us-gaap Number Of Reporting Units
NumberOfReportingUnits
1 pure
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Framingham
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
01702
CY2024Q1 dei City Area Code
CityAreaCode
617
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3390 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4599 usd
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3500 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
3500 usd
CY2024Q1 us-gaap Assets Noncurrent
AssetsNoncurrent
6890 usd
CY2023Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
8099 usd
CY2024Q1 us-gaap Assets
Assets
1540067 usd
CY2023Q3 us-gaap Assets
Assets
1958189 usd
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
2969520 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2304207 usd
CY2024Q1 us-gaap Interest Payable Current
InterestPayableCurrent
1026963 usd
CY2023Q3 us-gaap Interest Payable Current
InterestPayableCurrent
823128 usd
CY2024Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
363092 usd
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
12417551 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
9465921 usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2024Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0 usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
350000000
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4444364
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4444364
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
4689446
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
4689446
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
4444 usd
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
4689 usd
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
55324472 usd
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
54543188 usd
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-66206400 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-62055609 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-10877484 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-7507732 usd
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
1540067 usd
CY2024Q1 us-gaap Revenues
Revenues
31866 usd
CY2023Q1 us-gaap Revenues
Revenues
16654 usd
us-gaap Revenues
Revenues
77733 usd
us-gaap Revenues
Revenues
22914 usd
CY2024Q1 us-gaap Cost Of Revenue
CostOfRevenue
21555 usd
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
18718 usd
us-gaap Cost Of Revenue
CostOfRevenue
45161 usd
us-gaap Cost Of Revenue
CostOfRevenue
36353 usd
CY2024Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
683184 usd
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1252786 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1994534 usd
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
2355701 usd
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
203869 usd
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
170634 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
409449 usd
CY2024Q1 us-gaap Costs And Expenses
CostsAndExpenses
908608 usd
us-gaap Costs And Expenses
CostsAndExpenses
2724141 usd
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-1425484 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2371411 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-2701227 usd
CY2024Q1 us-gaap Interest Expense
InterestExpense
592397 usd
CY2023Q1 us-gaap Interest Expense
InterestExpense
635190 usd
us-gaap Interest Expense
InterestExpense
1779380 usd
us-gaap Interest Expense
InterestExpense
1159503 usd
CY2024Q1 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
0 usd
CY2023Q1 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
1158197 usd
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
0 usd
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
1158197 usd
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-592397 usd
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
523007 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1779380 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1306 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1469139 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-902477 usd
us-gaap Net Income Loss
NetIncomeLoss
-4150791 usd
us-gaap Net Income Loss
NetIncomeLoss
-2702533 usd
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.33
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.71
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.9
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-2.15
CY2024Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
4497111
CY2023Q1 us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1263585
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
4602623
us-gaap Weighted Average Number Of Shares Issued Basic
WeightedAverageNumberOfSharesIssuedBasic
1258099
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
-7507732 usd
CY2023Q4 us-gaap Net Income Loss
NetIncomeLoss
-2681652 usd
CY2023Q4 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
587959 usd
CY2023Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
25909 usd
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
-9575516 usd
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
-1469139 usd
CY2024Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
18280 usd
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
148891 usd
CY2024Q1 arch Exchange Of Common Stock Into Warrants
ExchangeOfCommonStockIntoWarrants
0 usd
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
-10877484 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-4192803 usd
CY2022Q4 us-gaap Net Income Loss
NetIncomeLoss
-1800056 usd
CY2022Q4 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
104026 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-5888833 usd
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-902477 usd
CY2023Q1 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
0 usd
CY2023Q1 arch Stock And Warrants Issued During Period Value New Issues Net Of Financing Costs
StockAndWarrantsIssuedDuringPeriodValueNewIssuesNetOfFinancingCosts
287420 usd
CY2023Q1 arch Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
49278 usd
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
68524 usd
us-gaap Depreciation
Depreciation
1209 usd
us-gaap Depreciation
Depreciation
1043 usd
us-gaap Share Based Compensation
ShareBasedCompensation
25909 usd
us-gaap Share Based Compensation
ShareBasedCompensation
172550 usd
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
-0 usd
us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
1158197 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
1437588 usd
us-gaap Paid In Kind Interest
PaidInKindInterest
846147 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-34911 usd
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-12464 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-185707 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-280058 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
665314 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1097894 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
341793 usd
us-gaap Increase Decrease In Interest Payable Net
IncreaseDecreaseInInterestPayableNet
313356 usd
arch Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
-104404 usd
arch Increase Decrease In Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherLiabilities
-112713 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1562764 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1249931 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
208530 usd
us-gaap Repayments Of Short Term Debt
RepaymentsOfShortTermDebt
212514 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
1125000 usd
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
230000 usd
us-gaap Proceeds From Issuance Of Unsecured Debt
ProceedsFromIssuanceOfUnsecuredDebt
450000 usd
us-gaap Proceeds From Issuance Of Unsecured Debt
ProceedsFromIssuanceOfUnsecuredDebt
515000 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
1366470 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
532486 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-196294 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-717445 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
222720 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
746940 usd
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26426 usd
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29495 usd
arch Warrants Exchanged For Common Stock Noncash
WarrantsExchangedForCommonStockNoncash
0 usd
arch Warrants Exchanged For Common Stock Noncash
WarrantsExchangedForCommonStockNoncash
49278 usd
arch Issuance Of Restricted Stock
IssuanceOfRestrictedStock
0 usd
arch Issuance Of Restricted Stock
IssuanceOfRestrictedStock
3019 usd
us-gaap Net Income Loss
NetIncomeLoss
-4150791 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1562764 usd
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Use of Estimates</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenue and expense during the reporting periods. Significant estimates include the assumptions used in the accrual for potential liabilities, the net realizable value of inventory, the valuation of debt and equity instruments, the fair value of derivative liabilities, valuation of equity instruments issued for services, and deferred tax valuation allowances. Actual results could differ from those estimates.</p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p>
CY2023Q1 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
1158197 usd
CY2024Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27567259
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1673136
CY2024Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><span style="text-decoration: underline; ">Concentration of Credit Risk</span></p> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"> </p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">Financial instruments that potentially subject the Company to concentration of credit risk consist primarily of cash. The Company maintains its cash in bank deposits accounts, which, at times, may exceed federally insured limits. The Company has not experienced any losses in such accounts. The Company believes it is not exposed to any significant credit risk on cash.</p>
CY2024Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
65980 usd
CY2023Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
40969 usd
CY2024Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
1263613 usd
CY2023Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
1323535 usd
CY2024Q1 us-gaap Inventory Net
InventoryNet
1329593 usd
CY2023Q3 us-gaap Inventory Net
InventoryNet
1364504 usd
CY2023Q1 us-gaap Gain Loss On Sale Of Derivatives
GainLossOnSaleOfDerivatives
1158197 usd
CY2024Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
46965 usd
us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
710897 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
102125
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
38
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y6M29D
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2023Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
1825
CY2023Q4 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
67
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
100300
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
38
CY2023Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P4Y
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
11000 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
0
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
0
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
12025
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
58
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
88275
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
35
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
74769
CY2024Q1 arch Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageExercisePrice
39
CY2024Q1 arch Share Based Compensation Arrangement By Share Based Payment Award Options Vested Weighted Average Remaining Contractual Term
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedWeightedAverageRemainingContractualTerm
P3Y6M
CY2024Q1 arch Share Based Compensation Arrangement By Share Based Payment Award Options Vested In Period Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedInPeriodAggregateIntrinsicValue
0 usd
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
88275
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
35
CY2024Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P5Y
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
0 usd

Files In Submission

Name View Source Status
arch-20240331_cal.xml Edgar Link unprocessable
arch-20240331_lab.xml Edgar Link unprocessable
0001437749-24-015699-index-headers.html Edgar Link pending
0001437749-24-015699-index.html Edgar Link pending
0001437749-24-015699.txt Edgar Link pending
0001437749-24-015699-xbrl.zip Edgar Link pending
arch-20240331.xsd Edgar Link pending
arch20240331_10q.htm Edgar Link pending
ex_664101.htm Edgar Link pending
ex_664102.htm Edgar Link pending
ex_664103.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
arch20240331_10q_htm.xml Edgar Link completed
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
arch-20240331_def.xml Edgar Link unprocessable
arch-20240331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable